20.09.19: Not intended for U.S. and UK Media - European Society for Medical Oncology (ESMO) Congress 2019

Bayer data at ESMO 2019 highlights innovation in cancer researchNew data for larotrectinib on durability of response in patients with TRK fusion cancer to be presented in a poster discussion on September 28 / Data from Bayer's prostate cancer franchise to be presented, including clinical relevance of drug-drug interactions in men with nmCRPC taking darolutamide and real-world data and pain evalutation data in men with mCRPC treated with radium-223 dichloride / New analyses from the Phase II study REGOBONE evaluating the efficacy and safety of regorafenib in patients with rare locally advanced or metastatic relapsed chondrosarcoma to be highlighted in an oral presentation on September 30mehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news